Related Experiment Videos
[Bisphosphonates]
1Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Japan.
Clinical Calcium
|December 4, 2004
Summary
Potent bisphosphonates like alendronate effectively prevent vertebral and non-vertebral fractures in osteoporosis patients. New formulations and sequential therapies promise improved treatment outcomes and patient quality of life.
Area of Science:
- Pharmacology
- Bone Biology
- Geriatrics
Context:
- Osteoporosis poses a significant health burden, leading to fractures and reduced quality of life.
- Bisphosphonates, such as alendronate and risedronate, are established treatments for osteoporosis.
- The efficacy of these agents extends to preventing both vertebral and non-vertebral fractures.
Purpose:
- To review the evidence supporting bisphosphonates in fracture prevention.
- To discuss novel formulations and combination therapies for osteoporosis.
- To highlight the potential impact of these advancements on patient outcomes and healthcare economics.
Summary:
- Potent bisphosphonates (alendronate, risedronate) demonstrate efficacy in preventing vertebral and non-vertebral fractures, with numbers needed to treat ranging from 30 to 90.
- Development is ongoing for once-weekly oral and long-acting intravenous bisphosphonates with extended bone resorption inhibition.
- Sequential therapy with parathyroid hormone (PTH) followed by alendronate shows additive benefits, suggesting improved osteoporosis management strategies.
Impact:
- Bisphosphonates are expected to improve the socio-economic aspects of osteoporosis treatment.
- Enhanced treatment options aim to improve survival rates and the quality of life for osteoporosis patients.
- Future therapeutic approaches combining or sequencing different modalities offer a promising outlook for osteoporosis management.